Pharmacological characterisation of CR6086, a potent prostaglandin E<sub>2</sub> receptor 4 antagonist, as a new potential disease-modifying anti-rheumatic drug.

Arthritis Res Ther · 2018 · PMC5831858 · PMID 29490676

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

The combination of CR6086 and 3 mg/kg MTX led to a highly significant improvement in the total combined histological score.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.